{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T04:44:23Z","timestamp":1791434663913,"version":"4.3.3"},"reference-count":143,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100001288","name":"Parkinson's Disease Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001288","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001449","name":"Alzheimer's Disease Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001449","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["CZ.02.1.01\/0.0\/0.0\/16_019\/0000868"],"award-info":[{"award-number":["CZ.02.1.01\/0.0\/0.0\/16_019\/0000868"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.ejphar.2024.176873","type":"journal-article","created":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T23:25:55Z","timestamp":1722986755000},"page":"176873","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Emerging pharmacological approaches for Huntington's disease"],"prefix":"10.1016","volume":"980","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8772-8157","authenticated-orcid":false,"given":"Kuldeep","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7220-5687","authenticated-orcid":false,"given":"Divya","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranshul","family":"Sethi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeetendra Kumar","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arpan Kumar","family":"Tripathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivendra","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satyajit D.","family":"Sarker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lutfun","family":"Nahar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Guru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2024.176873_bib1","doi-asserted-by":"crossref","DOI":"10.1186\/s40035-017-0101-9","article-title":"RNAi mechanisms in Huntington's disease therapy: siRNA versus shRNA","volume":"6","author":"Aguiar","year":"2017","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.ejphar.2024.176873_bib2","first-page":"191","article-title":"Personalized medicine: a tailor made medicine","volume":"6","author":"Akhondzadeh","year":"2014","journal-title":"Avicenna J. Med. Biotechnol. (AJMB)"},{"key":"10.1016\/j.ejphar.2024.176873_bib3","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1007\/s12035-022-03150-5","article-title":"CRISPR\/Cas9 mediated therapeutic approach in Huntington's disease","volume":"60","author":"Alkanli","year":"2023","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.ejphar.2024.176873_bib4","first-page":"2389","article-title":"Antisense oligonucleotide therapy for the nervous system: from bench to bedside with emphasis on pediatric neurology","volume":"14","author":"Amanat","year":"2022","journal-title":"Pharm. Times"},{"key":"10.1016\/j.ejphar.2024.176873_bib5","doi-asserted-by":"crossref","first-page":"323","DOI":"10.31887\/DCNS.2004.6.3\/kanderson","article-title":"Behavioral disturbances in Parkinson's disease","volume":"6","author":"Anderson","year":"2004","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.ejphar.2024.176873_bib6","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202002944","article-title":"Mesenchymal stem cells for neurological disorders","volume":"8","author":"Andrzejewska","year":"2021","journal-title":"Adv. Sci."},{"key":"10.1016\/j.ejphar.2024.176873_bib7","doi-asserted-by":"crossref","DOI":"10.1186\/s12970-021-00412-w","article-title":"Common questions and misconceptions about creatine supplementation: what does the scientific evidence really show?","volume":"18","author":"Antonio","year":"2021","journal-title":"J. Int. Soc. Sports Nutr."},{"key":"10.1016\/j.ejphar.2024.176873_bib8","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.5114\/aoms.2015.56342","article-title":"Brain-derived neurotrophic factor and its clinical implications","volume":"11","author":"Bathina","year":"2015","journal-title":"Arch. Med. Sci."},{"key":"10.1016\/j.ejphar.2024.176873_bib9","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1128\/CMR.00059-12","article-title":"Antimicrobial resistance and virulence: a successful or deleterious association in the bacterial world?","volume":"26","author":"Beceiro","year":"2013","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.ejphar.2024.176873_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/currents.RRN1260","article-title":"An international survey-based algorithm for the pharmacologic treatment of chorea in Huntington's disease","volume":"3","author":"Burgunder","year":"2011","journal-title":"PLoS Curr"},{"key":"10.1016\/j.ejphar.2024.176873_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.704281","article-title":"Antidepressant drugs effects on blood pressure","volume":"8","author":"Calvi","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.ejphar.2024.176873_bib12","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.jmb.2015.10.014","article-title":"Origins of programmable nucleases for genome engineering","volume":"428","author":"Chandrasegaran","year":"2016","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ejphar.2024.176873_bib13","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1038\/mt.2015.157","article-title":"Inhibition of aggregation of mutant huntingtin by nucleic acid aptamers in vitro and in a yeast model of Huntington's disease","volume":"23","author":"Chaudhary","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ejphar.2024.176873_bib14","doi-asserted-by":"crossref","first-page":"7204","DOI":"10.18632\/oncotarget.23208","article-title":"Inflammatory responses and inflammation-associated diseases in organs","volume":"9","author":"Chen","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejphar.2024.176873_bib15","doi-asserted-by":"crossref","first-page":"81","DOI":"10.4103\/0973-7847.120505","article-title":"Plants and phytochemicals for Huntington's disease","volume":"7","author":"Choudhary","year":"2013","journal-title":"Pharmacogn. Rev."},{"key":"10.1016\/j.ejphar.2024.176873_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1304342","article-title":"Antisense oligonucleotides: a novel Frontier in pharmacological strategy","volume":"14","author":"Collotta","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2024.176873_bib17","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s40265-016-0670-4","article-title":"Current pharmacological approaches to reduce chorea in Huntington's disease","volume":"77","author":"Coppen","year":"2017","journal-title":"Drugs"},{"issue":"77","key":"10.1016\/j.ejphar.2024.176873_bib18","first-page":"29","article-title":"Current pharmacological approaches to reduce chorea in Huntington's disease","volume":"771","author":"Coppen","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.ejphar.2024.176873_bib19","article-title":"Phenolic compounds of rhodiola rosea L. As the potential alternative therapy in the treatment of chronic diseases","volume":"24","author":"Cristina","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2024.176873_bib20","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.neuron.2010.12.035","article-title":"Huntington's disease: can mice lead the way to treatment?","volume":"69","author":"Crook","year":"2011","journal-title":"Neuron"},{"issue":"16","key":"10.1016\/j.ejphar.2024.176873_bib21","first-page":"1","article-title":"New approaches to symptomatic treatments for Alzheimer's disease","volume":"161","author":"Cummings","year":"2021","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.ejphar.2024.176873_bib22","article-title":"Cell rearrangement and oxidant\/antioxidant imbalance in Huntington's disease","volume":"12","author":"D'Egidio","year":"2023","journal-title":"Antioxidants"},{"key":"10.1016\/j.ejphar.2024.176873_bib23","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1007\/s13311-020-00891-w","article-title":"Therapeutic update on Huntington's disease: symptomatic treatments and emerging disease-modifying therapies","volume":"17","author":"Dash","year":"2020","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.ejphar.2024.176873_bib24","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s00213-015-4118-4","article-title":"Behavioral and neurochemical effects induced by reserpine in mice","volume":"233","author":"De Freitas","year":"2016","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.ejphar.2024.176873_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21093103","article-title":"Neural stem cell transplantation for neurodegenerative diseases","volume":"21","author":"De Gioia","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2024.176873_bib26","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1002\/mds.20235","article-title":"Effects of rivastigmine on motor and cognitive impairment in Huntington's disease","volume":"19","author":"de Tommaso","year":"2004","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ejphar.2024.176873_bib27","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1080\/14712598.2016.1183641","article-title":"Engineered BDNF producing cells as a potential treatment for neurologic disease","volume":"16","author":"Deng","year":"2016","journal-title":"Expet Opin. Biol. Ther."},{"key":"10.1016\/j.ejphar.2024.176873_bib28","article-title":"Huntington's disease: understanding its novel drugs and treatments","volume":"15","author":"Dhingra","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.ejphar.2024.176873_bib29","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S1474-4422(07)70220-X","article-title":"Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial","volume":"6","author":"Di Prospero","year":"2007","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejphar.2024.176873_bib30","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/ajmg.a.38494","article-title":"Therapy development in Huntington disease: from current strategies to emerging opportunities","volume":"A 176","author":"Dickey","year":"2018","journal-title":"Am. J. Med. Genet."},{"key":"10.1016\/j.ejphar.2024.176873_bib31","article-title":"Characterization of striatal neuronal loss and atrophy in the R6\/2 mouse model of Huntington's disease","volume":"6","author":"Dodds","year":"2014","journal-title":"PLoS Curr"},{"key":"10.1016\/j.ejphar.2024.176873_bib32","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3233\/JHD-200445","article-title":"What is the pathogenic CAG expansion length in Huntington's disease?","volume":"10","author":"Donaldson","year":"2021","journal-title":"J. Huntingtons. Dis."},{"key":"10.1016\/j.ejphar.2024.176873_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2021.705348","article-title":"MicroRNAs in Huntington's disease: diagnostic biomarkers or therapeutic agents?","volume":"15","author":"Dong","year":"2021","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.ejphar.2024.176873_bib143","doi-asserted-by":"crossref","first-page":"6660930","DOI":"10.1155\/2021\/6660930","article-title":"A systematic review and meta-analysis of risk factors associated with severity and death in COVID-19 patients","volume":"2021","author":"Du","year":"2021","journal-title":"Can. J. Infect. Dis. Med. Microbiol."},{"key":"10.1016\/j.ejphar.2024.176873_bib34","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/ana.20075","article-title":"Paroxetine retards disease onset and progression in Huntingtin mutant mice","volume":"55","author":"Duan","year":"2004","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ejphar.2024.176873_bib35","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/j.1476-5381.2011.01426.x","article-title":"Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease","volume":"164","author":"Duty","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2024.176873_bib36","article-title":"Omega-3 fatty acids and PPAR\u03b3 in cancer","volume":"14","author":"Edwards","year":"2008","journal-title":"PPAR Res."},{"key":"10.1016\/j.ejphar.2024.176873_bib37","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-04990-1","article-title":"Laquinimod treatment in the R6\/2 mouse model","volume":"7","author":"Ellrichmann","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2024.176873_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2022.972379","article-title":"Pharmacological attributes of Bacopa monnieri extract: current updates and clinical manifestation","volume":"9","author":"Fatima","year":"2022","journal-title":"Front. Nutr."},{"key":"10.1016\/j.ejphar.2024.176873_bib39","doi-asserted-by":"crossref","first-page":"3988","DOI":"10.1016\/j.apsb.2023.07.010","article-title":"Oxidative stress, the blood\u2013brain barrier and neurodegenerative diseases: the critical beneficial role of dietary antioxidants","volume":"13","author":"Feng","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejphar.2024.176873_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/11795735221092517","article-title":"Current and possible future therapeutic options for Huntington's disease","volume":"14","author":"Ferguson","year":"2022","journal-title":"J. Cent. Nerv. Syst. Dis."},{"key":"10.1016\/j.ejphar.2024.176873_bib41","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.bbadis.2009.04.001","article-title":"Mouse models of Huntington's disease and methodological considerations for therapeutic trials","volume":"1792","author":"Ferrante","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejphar.2024.176873_bib42","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1523\/JNEUROSCI.20-12-04389.2000","article-title":"Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease","volume":"20","author":"Ferrante","year":"2000","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejphar.2024.176873_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2021.101385","article-title":"Gene targeting techniques for Huntington's disease","volume":"70","author":"Fields","year":"2021","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.ejphar.2024.176873_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1101\/cshperspect.a007476","article-title":"Huntington's disease","volume":"3","author":"Finkbeiner","year":"2011","journal-title":"Cold Spring Harbor Perspect. Biol."},{"key":"10.1016\/j.ejphar.2024.176873_bib45","doi-asserted-by":"crossref","first-page":"657","DOI":"10.2147\/NDT.S6430","article-title":"Tetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease","volume":"6","author":"Frank","year":"2010","journal-title":"Neuropsychiatric Dis. Treat."},{"key":"10.1016\/j.ejphar.2024.176873_bib46","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1206506109","article-title":"Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6\/2 mice","volume":"109","author":"Garriga-Canut","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejphar.2024.176873_bib47","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-017-0307-1","article-title":"Gene suppression approaches to neurodegeneration","volume":"9","author":"Ghosh","year":"2017","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.ejphar.2024.176873_bib48","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1080\/14656566.2021.1876666","article-title":"State-of-the-art pharmacological approaches to reduce chorea in Huntington's Disease","volume":"22","author":"Gibson","year":"2021","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.ejphar.2024.176873_bib49","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1093\/hmg\/ddq464","article-title":"Meclizine is neuroprotective in models of Huntington's disease","volume":"20","author":"Gohil","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ejphar.2024.176873_bib50","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/cns.12655","article-title":"Mitochondrial dysfunction and biogenesis in neurodegenerative diseases: pathogenesis and treatment","volume":"23","author":"Golpich","year":"2017","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.ejphar.2024.176873_bib51","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1038\/sj.gt.3302920","article-title":"In vivo gene silencing in solid tumors by targeted electrically mediated siRNA delivery","volume":"14","author":"Golzio","year":"2007","journal-title":"Gene Ther."},{"key":"10.1016\/j.ejphar.2024.176873_bib52","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0011-393X(03)00059-6","article-title":"Cholinesterase inhibitors for the treatment of alzheimer's disease:: getting on and staying on","volume":"64","author":"Grossberg","year":"2003","journal-title":"Curr. Ther. Res. Clin. Exp."},{"key":"10.1016\/j.ejphar.2024.176873_bib53","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1111\/j.1460-9568.2005.04365.x","article-title":"Cognitive disorders and neurogenesis deficits in Huntington's disease mice are rescued by fluoxetine","volume":"22","author":"Grote","year":"2005","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.ejphar.2024.176873_bib54","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.bbi.2023.12.023","article-title":"Dietary fibre confers therapeutic effects in a preclinical model of Huntington's disease","volume":"116","author":"Gubert","year":"2024","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.ejphar.2024.176873_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.103687","article-title":"Gene-environment-gut interactions in Huntington's disease mice are associated with environmental modulation of the gut microbiome","volume":"25","author":"Gubert","year":"2022","journal-title":"iScience"},{"key":"10.1016\/j.ejphar.2024.176873_bib56","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1177\/1756285613499424","article-title":"Efficacy and safety of laquinimod in multiple sclerosis: current status","volume":"6","author":"Haggiag","year":"2013","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.ejphar.2024.176873_bib57","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-022-01134-4","article-title":"Stem cell-based therapy for human diseases","volume":"7","author":"Hoang","year":"2022","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejphar.2024.176873_bib58","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/j.cell.2013.11.024","article-title":"Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders","volume":"155","author":"Hsiao","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2024.176873_bib59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s41100-019-0246-3","article-title":"Constipation in chronic kidney disease: it is time to reconsider","volume":"5","author":"Ikee","year":"2019","journal-title":"Ren. Replace. Ther."},{"key":"10.1016\/j.ejphar.2024.176873_bib60","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci12101389","article-title":"Pathogenesis of Huntington's disease: an emphasis on molecular pathways and prevention by natural remedies","volume":"12","author":"Irfan","year":"2022","journal-title":"Brain Sci."},{"key":"10.1016\/j.ejphar.2024.176873_bib61","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.3390\/brainsci12101389","article-title":"Pathogenesis of Huntington's disease: an emphasis on molecular pathways and prevention by natural remedies","volume":"12","author":"Irfan","year":"2022","journal-title":"Brain Sci."},{"key":"10.1016\/j.ejphar.2024.176873_bib62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms22052719","article-title":"The role of tumor necrosis factor alpha (TNF-\u03b1) in autoimmune disease and current TNF-\u03b1 inhibitors in therapeutics","volume":"22","author":"Jang","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2024.176873_bib63","doi-asserted-by":"crossref","DOI":"10.3390\/biom11071007","article-title":"Memantine and riluzole exacerbate, rather than ameliorate behavioral deficits induced by 8-oh-dpat sensitization in a spatial task","volume":"11","author":"Janikova","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.ejphar.2024.176873_bib64","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.769184","article-title":"Molecular strategies to target protein aggregation in Huntington's disease","volume":"8","author":"Jarosi\u0144ska","year":"2021","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.ejphar.2024.176873_bib65","article-title":"Bacterial delivery of TALEN proteins for human genome editing","volume":"9","author":"Jia","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2024.176873_bib66","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1088124","article-title":"Neuroinflammation in Huntington's disease: from animal models to clinical therapeutics","volume":"13","author":"Jia","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejphar.2024.176873_bib67","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241613021","article-title":"From pathogenesis to therapeutics: a review of 150 Years of Huntington's disease research","volume":"24","author":"Jiang","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"30","key":"10.1016\/j.ejphar.2024.176873_bib68","first-page":"1","article-title":"Small interfering RNA (siRNA)-based therapeutic applications against viruses: principles, potential, and challenges","volume":"301","author":"Kang","year":"2023","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.ejphar.2024.176873_bib69","doi-asserted-by":"crossref","first-page":"4677","DOI":"10.1093\/nar\/gky264","article-title":"Clustered regularly interspaced short palindromic repeats (CRISPR)\/CRISPR-associated protein 9 with improved proof-reading enhances homology-directed repair","volume":"46","author":"Kato-Inui","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejphar.2024.176873_bib70","doi-asserted-by":"crossref","first-page":"8363","DOI":"10.3390\/ijms22168363","article-title":"New avenues for the treatment of Huntington's disease","volume":"22","author":"Kim","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2024.176873_bib71","doi-asserted-by":"crossref","first-page":"8363","DOI":"10.3390\/ijms22168363","article-title":"New avenues for the treatment of Huntington's disease","volume":"22","author":"Kim","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2024.176873_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2020.105199","article-title":"An integrated metagenomics and metabolomics approach implicates the microbiota-gut-brain axis in the pathogenesis of Huntington's disease","volume":"148","author":"Kong","year":"2021","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ejphar.2024.176873_bib73","doi-asserted-by":"crossref","first-page":"6634","DOI":"10.1021\/acs.chemrev.1c00795","article-title":"Recent developments for the deuterium and tritium labeling of organic molecules","volume":"122","author":"Kopf","year":"2022","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejphar.2024.176873_bib74","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2023.1184060","article-title":"The potential for mitochondrial therapeutics in the treatment of primary open-angle glaucoma: a review","volume":"14","author":"Kuang","year":"2023","journal-title":"Front. Physiol."},{"key":"10.1016\/j.ejphar.2024.176873_bib75","article-title":"Increased body weight of the BAC HD transgenic mouse model of Huntington's disease accounts for some but not all of the observed HD-like motor deficits","volume":"5","author":"Kudwa","year":"2013","journal-title":"PLoS Curr"},{"key":"10.1016\/j.ejphar.2024.176873_bib76","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci10010043","article-title":"Therapeutic advances for Huntington's disease","volume":"10","author":"Kumar","year":"2020","journal-title":"Brain Sci."},{"key":"10.1016\/j.ejphar.2024.176873_bib77","doi-asserted-by":"crossref","first-page":"e92","DOI":"10.1038\/emi.2016.97","article-title":"Converting monoclonal antibody-based immunotherapies from passive to active: bringing immune complexes into play","volume":"5","author":"Lambour","year":"2016","journal-title":"Emerg. Microb. Infect."},{"key":"10.1016\/j.ejphar.2024.176873_bib78","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1186\/s12967-023-04272-7","article-title":"Efficacy of low-dose risperidone in combination with sertraline in first-episode drug-na\u00efve patients with schizophrenia: a randomized controlled open-label study","volume":"21","author":"Lang","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.ejphar.2024.176873_bib79","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.cell.2022.11.001","article-title":"Hallmarks of aging: an expanding universe","volume":"186","author":"L\u00f3pez-Ot\u00edn","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2024.176873_bib80","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242316798","article-title":"Mutant-huntingtin molecular pathways elucidate new targets for drug repurposing","volume":"24","author":"Makeeva","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2024.176873_bib81","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.02021","article-title":"Anti-inflammatory and neuroprotective agents in clinical trials for CNS disease and injury: where do we go from here?","volume":"11","author":"Mallah","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejphar.2024.176873_bib82","doi-asserted-by":"crossref","DOI":"10.3390\/antiox11112293","article-title":"Coenzyme Q10: role in less common age-related disorders","volume":"11","author":"Mantle","year":"2022","journal-title":"Antioxidants"},{"key":"10.1016\/j.ejphar.2024.176873_bib83","first-page":"1813","article-title":"Pictorial review of glutamate excitotoxicity: fundamental concepts for neuroimaging","volume":"22","author":"Mark","year":"2001","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"10.1016\/j.ejphar.2024.176873_bib84","first-page":"36","article-title":"Antipsychotic-induced movement disorders: evaluation and treatment","volume":"2","author":"Mathews","year":"2005","journal-title":"Psychiatry (Edgmont)"},{"key":"10.1016\/j.ejphar.2024.176873_bib85","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.euroneuro.2021.05.010","article-title":"Drug development for autism spectrum disorder (ASD): progress, challenges, and future directions","volume":"48","author":"McCracken","year":"2021","journal-title":"Eur. Neuropsychopharmacol"},{"key":"10.1016\/j.ejphar.2024.176873_bib86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1101\/cshperspect.a008656","article-title":"Caspase functions in cell death and disease","volume":"5","author":"McIlwain","year":"2013","journal-title":"Cold Spring Harbor Perspect. Biol."},{"key":"10.1016\/j.ejphar.2024.176873_bib87","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2012.00088","article-title":"Cognitive impairment and dementia in Parkinson's disease: clinical features, diagnosis, and management","volume":"3","author":"Meireles","year":"2012","journal-title":"Front. Neurol."},{"key":"10.1016\/j.ejphar.2024.176873_bib88","article-title":"Therapeutic interventions for disease progression in Huntington's disease","author":"Mestre","year":"2009","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ejphar.2024.176873_bib89","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2019.00363","article-title":"Brain-derived neurotrophic factor: a key molecule for memory in the healthy and the pathological brain","volume":"13","author":"Miranda","year":"2019","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.ejphar.2024.176873_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.121153","article-title":"Modulating autophagy and mitophagy as a promising therapeutic approach in neurodegenerative disorders","volume":"311","author":"Mishra","year":"2022","journal-title":"Life Sci."},{"key":"10.1016\/j.ejphar.2024.176873_bib91","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4137\/IMI.S25054","article-title":"Current perspectives on the beneficial role of ginkgo biloba in neurological and cerebrovascular disorders","volume":"10","author":"Nash","year":"2015","journal-title":"Integr. Med. Insights"},{"key":"10.1016\/j.ejphar.2024.176873_bib92","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2020.548505","article-title":"Glutamate systems in DSM-5 anxiety disorders: their role and a review of glutamate and GABA psychopharmacology","volume":"11","author":"Nasir","year":"2020","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.ejphar.2024.176873_bib93","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.626010","article-title":"Role of cannabidiol in the therapeutic intervention for substance use disorders","volume":"12","author":"Navarrete","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2024.176873_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112117","article-title":"Nanotechnology-based drug delivery for central nervous system disorders","volume":"143","author":"Nguyen","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejphar.2024.176873_bib95","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/3164734","article-title":"The role of the reactive oxygen species and oxidative stress in the pathomechanism of the age-related ocular diseases and other pathologies of the anterior and posterior eye segments in adults","author":"Nita","year":"2016","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.ejphar.2024.176873_bib96","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/6462120","article-title":"Omega-3 fatty acids: possible neuroprotective mechanisms in the model of global ischemia in rats","volume":"2016","author":"Nobre","year":"2016","journal-title":"J. Nutr. Metab"},{"key":"10.1016\/j.ejphar.2024.176873_bib97","first-page":"545","article-title":"Tetrabenazine in the treatment of Huntington's disease","volume":"3","author":"Paleacu","year":"2007","journal-title":"Neuropsychiatric Dis. Treat."},{"key":"10.1016\/j.ejphar.2024.176873_bib98","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci7060067","article-title":"Neuropsychiatric burden in Huntington's disease","volume":"7","author":"Paoli","year":"2017","journal-title":"Brain Sci."},{"key":"10.1016\/j.ejphar.2024.176873_bib99","series-title":"Neurobiol. Brain Disord. Biol. Basis Neurol. Psychiatr. Disord","first-page":"275","article-title":"Huntington disease","author":"Parsons","year":"2023"},{"key":"10.1016\/j.ejphar.2024.176873_bib100","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.3389\/fneur.2019.01315","article-title":"Therapeutic applications of cysteamine and cystamine in neurodegenerative and neuropsychiatric diseases","volume":"10","author":"Paul","year":"2019","journal-title":"Front. Neurol."},{"key":"10.1016\/j.ejphar.2024.176873_bib101","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.expneurol.2007.10.015","article-title":"The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6\/2 Huntington's disease mouse model","volume":"210","author":"Peng","year":"2008","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ejphar.2024.176873_bib102","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2174\/1570159X14666161017233642","article-title":"The role of electroconvulsive therapy (ECT) in bipolar disorder: effectiveness in 522 patients with bipolar depression, mixed-state, mania and catatonic features","volume":"15","author":"Perugi","year":"2017","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.ejphar.2024.176873_bib103","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1089\/hum.2017.199","article-title":"Artificial miRNAs reduce human mutant huntingtin throughout the striatum in a transgenic sheep model of Huntington's disease","volume":"29","author":"Pfister","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ejphar.2024.176873_bib104","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.cub.2009.03.030","article-title":"Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients","volume":"19","author":"Pfister","year":"2009","journal-title":"Curr. Biol."},{"key":"10.1016\/j.ejphar.2024.176873_bib105","article-title":"Neuroprotective mechanisms of resveratrol in alzheimer's disease: role of SIRT1","author":"Quadros Gomes","year":"2018","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.ejphar.2024.176873_bib106","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.3390\/antiox12071418","article-title":"Exploitation of quercetin's antioxidative properties in potential alternative therapeutic options for neurodegenerative diseases","volume":"12","author":"Rarinca","year":"2023","journal-title":"Antioxidants"},{"key":"10.1016\/j.ejphar.2024.176873_bib107","doi-asserted-by":"crossref","DOI":"10.1016\/j.conb.2022.102652","article-title":"Microbiota-immune-brain interactions: a lifespan perspective","volume":"78","author":"Ratsika","year":"2023","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1016\/j.ejphar.2024.176873_bib108","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s40259-022-00519-9","article-title":"Antisense oligonucleotide therapy: from design to the Huntington disease clinic","volume":"36","author":"Rook","year":"2022","journal-title":"BioDrugs"},{"key":"10.1016\/j.ejphar.2024.176873_bib109","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s42466-023-00285-1","article-title":"Symptomatic treatment options for Huntington's disease (guidelines of the German Neurological Society)","volume":"5","author":"Saft","year":"2023","journal-title":"Neurol. Res. Pract"},{"key":"10.1016\/j.ejphar.2024.176873_bib110","doi-asserted-by":"crossref","first-page":"485","DOI":"10.3389\/fchem.2020.00485","article-title":"Strategies to investigate ubiquitination in Huntington's disease","volume":"8","author":"Sap","year":"2020","journal-title":"Front. Chem."},{"key":"10.1016\/j.ejphar.2024.176873_bib111","doi-asserted-by":"crossref","first-page":"89","DOI":"10.59566\/IJBS.2011.7089","article-title":"Huntington's disease: from mutant huntingtin protein to neurotrophic factor therapy","volume":"7","author":"Sari","year":"2011","journal-title":"Int. J. Biomed. Sci."},{"key":"10.1016\/j.ejphar.2024.176873_bib112","doi-asserted-by":"crossref","first-page":"904","DOI":"10.3390\/ijms17060904","article-title":"Neuroprotective and therapeutic strategies against Parkinson's disease: recent perspectives","volume":"17","author":"Sarkar","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2024.176873_bib113","doi-asserted-by":"crossref","DOI":"10.3390\/nu13072232","article-title":"Therapeutic effects of catechins in less common neurological and neurodegenerative disorders","volume":"13","author":"Sebastiani","year":"2021","journal-title":"Nutrients"},{"key":"10.1016\/j.ejphar.2024.176873_bib114","doi-asserted-by":"crossref","first-page":"113","DOI":"10.25122\/jml-2018-0075","article-title":"A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease","volume":"12","author":"Seyedian","year":"2019","journal-title":"J. Med. Life"},{"key":"10.1016\/j.ejphar.2024.176873_bib115","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3389\/fphar.2020.01021","article-title":"Turmeric and its major compound curcumin on health: bioactive effects and safety profiles for food, pharmaceutical, biotechnological and medicinal applications","volume":"11","author":"Sharifi-Rad","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2024.176873_bib116","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/bpa.12429","article-title":"The role of the human globus pallidus in Huntington's disease","volume":"26","author":"Singh-Bains","year":"2016","journal-title":"Brain Pathol."},{"key":"10.1016\/j.ejphar.2024.176873_bib117","doi-asserted-by":"crossref","DOI":"10.1016\/j.jff.2022.105047","article-title":"Dietary and nutraceutical-based therapeutic approaches to combat the pathogenesis of Huntington's disease","volume":"92","author":"Singh","year":"2022","journal-title":"J. Funct.Foods"},{"key":"10.1016\/j.ejphar.2024.176873_bib118","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.nbd.2015.01.002","article-title":"Anti-semaphorin 4D immunotherapy ameliorates neuropathology and some cognitive impairment in the YAC128 mouse model of Huntington disease","volume":"76","author":"Southwell","year":"2015","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ejphar.2024.176873_bib119","first-page":"597","article-title":"Coenzyme Q10 effects in neurodegenerative disease","volume":"5","author":"Spindler","year":"2009","journal-title":"Neuropsychiatric Dis. Treat."},{"issue":"10","key":"10.1016\/j.ejphar.2024.176873_bib120","first-page":"1","article-title":"Increased intestinal permeability and gut dysbiosis in the R6\/2 mouse model of Huntington's disease","volume":"101","author":"Stan","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2024.176873_bib121","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1089\/hum.2013.200","article-title":"Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington's disease","volume":"25","author":"Stanek","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ejphar.2024.176873_bib122","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1127704","article-title":"Immunomodulation\u2014a general review of the current state-of-the-art and new therapeutic strategies for targeting the immune system","volume":"14","author":"Strzelec","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejphar.2024.176873_bib123","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nrn3707","article-title":"Growth and folding of the mammalian cerebral cortex: from molecules to malformations","volume":"15","author":"Sun","year":"2014","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.ejphar.2024.176873_bib124","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.drudis.2016.05.015","article-title":"Drug combination therapy increases successful drug repositioning","volume":"21","author":"Sun","year":"2016","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejphar.2024.176873_bib125","doi-asserted-by":"crossref","first-page":"852","DOI":"10.5588\/ijtld.16.0584","article-title":"Addressing the tuberculosis\u2013depression syndemic to end the tuberculosis epidemic","volume":"21","author":"Sweetland","year":"2017","journal-title":"Int. J. Tubercul. Lung Dis."},{"key":"10.1016\/j.ejphar.2024.176873_bib126","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1474-4422(22)00121-1","article-title":"Potential disease modifying therapies for Huntington's disease, lessons learned and future opportunities","volume":"21","author":"Tabrizi","year":"2022","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejphar.2024.176873_bib127","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.neuron.2019.01.039","article-title":"Huntingtin lowering strategies for disease modification in Huntington's disease","volume":"101","author":"Tabrizi","year":"2019","journal-title":"Neuron"},{"key":"10.1016\/j.ejphar.2024.176873_bib128","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.nbd.2009.11.004","article-title":"Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention","volume":"37","author":"Tansey","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ejphar.2024.176873_bib129","first-page":"1","article-title":"Medications for psychosis: dopamine blockers and dopamine partial agonists (antipsychotics)","author":"Uchida","year":"2023","journal-title":"Tasman\u2019s Psychiatry"},{"issue":"6","key":"10.1016\/j.ejphar.2024.176873_bib142","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20190812","article-title":"CNS-localized myeloid cells capture living invading T cells during neuroinflammation","volume":"217","author":"Wasser","year":"2020","journal-title":"J Exp Med"},{"key":"10.1016\/j.ejphar.2024.176873_bib130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/JHD-170267","article-title":"Pridopidine: overview of pharmacology and rationale for its use in Huntington's disease","volume":"7","author":"Waters","year":"2018","journal-title":"J. Huntingtons. Dis."},{"key":"10.1016\/j.ejphar.2024.176873_bib131","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S1474-4422(17)30280-6","article-title":"Therapies targeting DNA and RNA in Huntington's disease","volume":"16","author":"Wild","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejphar.2024.176873_bib132","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2020.104963","article-title":"The contribution of glial cells to Huntington's disease pathogenesis","volume":"143","author":"Wilton","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ejphar.2024.176873_bib133","first-page":"2923","article-title":"N-acetylcysteine modulates glutamatergic dysfunction and depressive behavior in Huntington's disease","volume":"25","author":"Wright","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ejphar.2024.176873_bib134","doi-asserted-by":"crossref","DOI":"10.3390\/ph16081085","article-title":"The disruption of NMDAR\/TRPM4 death signaling with TwinF interface inhibitors: a new pharmacological principle for neuroprotection","volume":"16","author":"Yan","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejphar.2024.176873_bib135","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1002\/mds.25654","article-title":"Unified Huntington's disease rating scale for advanced patients: validation and follow-up study","volume":"28","author":"Youssov","year":"2013","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ejphar.2024.176873_bib136","doi-asserted-by":"crossref","DOI":"10.3390\/cells11233779","article-title":"Evidences for mutant huntingtin inducing musculoskeletal and brain growth impairments via disturbing testosterone biosynthesis in male Huntington disease animals","volume":"11","author":"Yu-Taeger","year":"2022","journal-title":"Cells"},{"issue":"10","key":"10.1016\/j.ejphar.2024.176873_bib137","first-page":"1","article-title":"The alteration of gut microbiome and metabolism in amyotrophic lateral sclerosis patients","volume":"101","author":"Zeng","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2024.176873_bib138","doi-asserted-by":"crossref","first-page":"9779","DOI":"10.1073\/pnas.1630797100","article-title":"MicroRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms","volume":"100","author":"Zeng","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejphar.2024.176873_bib139","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.4252\/wjsc.v13.i9.1278","article-title":"Neural stem cell therapy for brain disease","volume":"13","author":"Zhao","year":"2021","journal-title":"World J. Stem Cell."},{"key":"10.1016\/j.ejphar.2024.176873_bib140","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/B978-0-12-385883-2.00010-2","article-title":"Huntington disease and the huntingtin protein","volume":"107","author":"Zheng","year":"2012","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"10.1016\/j.ejphar.2024.176873_bib141","article-title":"Kainic acid-induced neurodegenerative model: potentials and limitations","author":"Zhu","year":"2011","journal-title":"J. Biomed. Biotechnol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299924005624?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299924005624?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T13:35:18Z","timestamp":1742391318000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299924005624"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":143,"alternative-id":["S0014299924005624"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2024.176873","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging pharmacological approaches for Huntington's disease","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2024.176873","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"176873"}}